{"url_path":"/sec/oncy/8-k/2026-06-16/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000041-index.html","accession_number":"0001129928-26-000041","cik":"0001129928","ticker":"ONCY","issuer_name":"ONCOLYTICS BIOTECH INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000041-index.html","primary_entity_key":"0001129928","primary_entity_name":"ONCOLYTICS BIOTECH INC"},"word_count":79,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn June 16, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing a new patent related to the manufacturing of pelareorep and additional updates related to pelareorep's intellectual property portfolio. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section."}